Major Depressive Disorder
Arrivo Bio initiates phase 2b trial of SIRT6 activator for major depressive disorder
Arrivo Bio has dosed the first patient in a phase 2b clinical trial of SP-624, a novel SIRT6 activator being evaluated as a treatment for major depressive disorder, the company announced in a press release.
Menopause transition does not increase risk for depressive symptoms for all women
Women are not universally at risk for depressive symptoms during menopause transition, but providers should be aware of risk factors and treat mental health disorders promptly, according to a review published in The Lancet.
Neurocrine announces phase 1 study of VMAT2 inhibitor, dosing in phase 2 study of MDD drug
Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.
FDA clears prescription digital therapeutic for adults with major depressive disorder
The FDA has cleared a first-of-its-kind prescription digital therapeutic to treat major depressive disorder symptoms as an adjunct to clinician-managed outpatient care in adults who have been prescribed antidepressants.
FDA grants clearance to TMS device for MDD in young people
The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.
FDA grants breakthrough designation to psilocybin analog for major depressive disorder
The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.
Smoking, high BMI drive relationship between PAD, major depressive disorder
The elevated propensity for peripheral artery disease in patients with major depression may be mediated by increased liability for lifetime smoking and BMI, according to research in the Journal of the American Heart Association.
Sleep improvement in hospital greater for those with acute mania compared with MDD
Individuals with mania who were admitted to an acute care psychiatric unit saw greater sleep improvement than patients with major depressive disorder, according to a study.
AbbVie acquires Cerevel, boosting roster of therapeutic candidates
AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.
Prevalence of MDD twice that of generalized anxiety disorder among those with epilepsy
ORLANDO — Among individuals with epilepsy, the prevalence of a major depressive disorder diagnosis was almost doubled compared with generalized anxiety disorder and varied by type of antiseizure medication used, according to a poster.